Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era

Clinical Transplantation

Volumn 10, Issue 2, 1996, Pages 186-190

  Hariharan, Sundaram ^a   Alexander, J Wesley ^a   Schroeder, Timothy J ^a   First, M Roy ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Cadaveric renal transplantation; Graft function; Graft survival; Induction treatments

Indexed keywords

CREATININE; CYCLOSPORIN; CYCLOSPORIN A; LYMPHOBLAST ANTIBODY; OKT 3; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CADAVER DONOR; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANTILYMPHOCYTE SERUM; CADAVER; CREATININE; CYCLOSPORINE; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MUROMONAB-CD3; REOPERATION; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0029972675     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. STARZL TE, MARCHIORO TL. PORTER KA, IWASAKI Y, CERILLI GJ. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and human renal homotransplantation. Surg Gynecol Obstet 1967: 124:301.
2. SHEIL AGR, KELLY GE, STOREY GB. Controlled clinical trial of antilymphocyte globulin in patients with renal allografts from cadaver donors. Lancet 1971: 1: 359.
3. NAJARIAN JS, SIMMONS SL, CONTI RM, et al. Seven years experience with antilymphoblast in patients with renal allografts from cadaver donors. Ann Surg 1976: 184: 352.
4. NOVICK AC. Symposium on renal transplantation. Urol Clin N Am 1983: 10: 253.
5. WECHTER WJ, BRODIE JA, MORELL RM. RAFJ M, SCHULTZ JR. Antithymocyte globulin (ATGAM) in renal allograft recipients. Multicenter trial using a 14-dose regimen. Transplantation 1979: 28: 294.
6. WAKABAYASHI H, COOK DJ, KING A, MENDEZ-PICOW G, BROWN K, LEE HM. Batch-to-batch variations in rabbit antithymocyte globulin preparation. Transplant Proc 1991: 23: 1125.
7. KUPIN WL, VENKATACHALAM KK, OH HK, DIENST S, LEVIN NW. Sequential use of Minnesota antilymphoblast globulin and cyclosporine in cadaveric renal transplantation. Transplantation 1985: 40: 601.
8. KAPLAN EL, MEIER P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958: 53: 457.
9. TAYLOR HE, AIKMANN CFD, HOROWITZ I. Canadian clinical trial of antilymphocyte globulin in human cadaveric renal transplantation. Can Med Assoc J 1976: 115: 1205.
10. TURCOTTE JG, FEDUSKA NJ, HAINES RF, et al. Antilymphocyte globulin in renal transplant recipients. Arch Surg 1973: 106: 484.
11. BIRTCH AG, CARPENTER CB, TILNEY NI, et al. A controlled clinical trial of antilymphocyte globulin in human allograft. Transplant Proc 1971: 3: 762.
12. TOLEDO-PEREYRA LH, BERGGREN C, MITTAL VK, WHITTEN JI, BASKIN S, MCNICHOL L. A prospective randomized comparison of antilymphoblast globulin versus antithymocyte globulin for cadaveric kidney transplantation. Transplantation 1985: 40: 448.
13. PESCOVITZ MD, BOOK BK, MILGROM ML, LEAPMAN SB, PETERSEN B, FILO RS. Comparison of Minnesota antilymphoblast globulin and Upjohn antithymocyte globulin for induction immunosuppression of human renal allografts. Surgery 1994: 116:811.
14. LUM CT, UMEN AJ, KASISKE B, et al. Clinical impact of replacing Minnesota antilymphocyte globulin with AT-GAM. Transplantation 1995: 59: 371.
15. VIGERAL P, CHKOFF N, CHATENOUD L. et al. Prophylactic use of OKT3 monoclonal in cadaveric kidney recipients. Transplantation 1986: 41: 730.
16. DEBURE A, CHKOFF N, CHATENOUD L, et al. One month prophylactic use of OKT3 in cadaver kidney transplant revipients. Transplantation 1988: 45: 546.
17. KREIS H, CHKOFF N, CHATENAUD L, et al. A randomized trial comparing the efficacy of OkT3 used to prevent or to treat rejection. Transplant Proc 1989: 21: 3.
18. ACKERMAN JR, LEFOR WM, KAHANA L, WEINSTEIN S. SHIRES DL. Prophylactic use of OKT3 in renal transplantation: Part of a prospective randomized multicenter trial. Transplant Proc 1988: 20: 242.
19. DEPAUW L, ABRAMOWICZ D, GOLDMAN M, VEREESTRAETEN P, KINNAERT P, TOUSSANT C. Comparison between prophylactic use of OKT3 and cyclosporine in cadaver renal transplantation. Transplant Proc 1990: 22: 1759.
20. GONWA TA, BRONKER K, HUSBERG B, et al. Short course OKT3 induction for primary cadaveric renal transplantation. J Am Soc Nephrol (Abstract) 1993: 938.
21. ABRAMOWICZ D, GOLDMAN M, DEPAUW L, VANHERWEGHEM JL, KINNAERT P, VEREESTRAETEN P. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation - A single center, prospective randomized study. Transplantation 1992: 54: 433.
22. NORMAN DJ, KAHANA L, STUART JR. FP, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993. 55: 44.
23. BROYER M, GAGNADOUX MF, GUEST G, et al. Prophylactic OKT3 monoclonal antibody versus antilymphocyte globulin: A prospective, randomized study on 148 first cadaver kidney grafts. Transplant Proc 1993: 25: 570.
24. STEINMULLER DR, HAYER JM, NOVICK AC, et al. Comparison of OKT3 with ALG for prophylaxis for patients with acute renal failure after cadaveric renal transplantation. Transplantation 1991: 52: 67.
25. GRINO J, CASTELAO AM, SERAN D, et al. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: A prospective randomized study. Am J Kidney Dis 1992: 20: 603.
26. HANTO DW, JENDRISAK MD, SO SKS, et al. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Transplantation 1994: 57: 377.
27. FISHER RA, TCHERVENKOV JI, SCHROEDFR TJ, et al. Efficacy of induction therapy in cadaveric renal transplantation comparing rabbit antithymocyte serum and Minnesota antilymphoblast globulin. Transplant Proc 1991: 23: 1253.
28. SCHROEDER TJ, FIRST MR, MANSOUR ME, ALEXANDER JW, PENN I. Prophylactic use of OKT3 in immunologic highrisk cadaver renal transplant recipients. Clin Transplantation 1989: 14(2): 14.
29. COLE EH, CATTRAN DC, FAREWELL VT, et al. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection. Transplantation 1994: 57: 60.